このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発または難治性多発性骨髄腫患者を対象としたIBI3003の研究

2026年9月22日 更新者:Fortvita Biologics (USA)Inc.

再発または難治性多発性骨髄腫患者におけるIBI3003の第I/II相、多施設共同、非盲検試験

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

360

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Arizona
      • Scottsdale、Arizona、アメリカ、85258
        • 積極的、募集していない
        • Honor Health
    • California
      • Duarte、California、アメリカ、91010
      • Irvine、California、アメリカ、92618
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 積極的、募集していない
        • Emory
    • New York
      • New York、New York、アメリカ、10021
    • Texas
      • Houston、Texas、アメリカ、77030

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria

Participants in Parts 1 & 2 must satisfy all of the following criteria to be enrolled in the study:

  1. Age ≥18 years.

  2. Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.

    Multiple myeloma is defined as clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma, and any one or more of the following myelomadefining events:

    • Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or corrected serum calcium >2.75 mmol/L (>11 mg/dL) Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 μmol/L (>2 mg/dL) Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
    • Any one or more of the following biomarkers of malignancy:

    Clonal bone marrow plasma cell percentage ≥60% Involved: uninvolved serum free light chain ratio ≥100 (involved FLC level must be

    ≥100 mg/L) >1 focal lesions on MRI studies (at least 5 mm in size)

  3. Relapsed or refractory measurable multiple myeloma (R/R MM) following prior treatment with ≥3 lines of systemic anti-myeloma therapy that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy, and with limited or no therapeutic options that are likely to offer a favorable risk/benefit profile; participants must be relapsed or refractory to their last anti-myeloma regimen.

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

  5. At least one of the following measurable disease indicators:

    • Serum M-protein ≥5 g/L (for IgA and IgD subtypes, quantitative immunoglobin measurements could be used as substitutions for M-protein)
    • Urine M-protein ≥200 mg/24h
    • Serum free light chain (FLC) test: affected FLC level ≥100 mg/L and abnormal serum FLC ratio (<0.26 or >1.65)
  6. Adequate hematologic, hepatic, renal and cardiac function:

    • Blood count: absolute neutrophil count ≥1.0×10^9/L, hemoglobin ≥70 g/L, and platelet count ≥50×10^9/L (values must be achieved without growth factors or blood transfusions within 7 days prior to first dose)
    • Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤2.5× upper limit of normal (ULN) and total bilirubin (TBIL) ≤1.5×ULN
    • Renal function: calculated creatinine ≥30 mL/min by the Cockcroft-Gault Equation
    • Cardiac function: Left ventricular ejection fraction (LVEF) ≥50%
  7. Life expectancy ≥3 months.

  8. Women of childbearing potential and fertile men who are sexually active must agree to use a highly effective method of contraception (<1% / year failure rate) during the study and for 90 days after the last dose level of study drug. Contraception must be consistent with local regulations or standards regarding the use of birth control methods by participants participating in clinical trials. Women and men must agree not to donate or bank eggs (ova, oocytes) or sperm, respectively, during the study and for 90 days after the last dose level of study drug.

  9. Participants with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.

  10. Willing and able to adhere to the complete schedule of assessments and all prohibitions and restrictions specified in this protocol

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.

  2. Active amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or solitary plasmacytoma, or smoldering multiple myeloma (MM) as defined by the IMWG criteria.

  3. Spinal cord compression that results in limited self-care at present or within 6 months prior to informed consent, or that is expected to cause such limitations during Study participation.

  4. History of primary immunodeficiency.

  5. Current or previous other malignancy within 3 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy.

  6. Allogeneic hematopoietic stem cell transplantation within the last 6 months, or autologous stem cell transplantation within the last 3 months prior to the first administration of the study drug.

  7. History of organ transplantation.

  8. Active graft-versus-host disease.

  9. Thromboembolism or cerebrovascular events (e.g., myocardial infarction, unstable angina, transient ischemic attack, cerebrovascular accident, deep vein thrombosis [unless associated with complications of central venous access], or pulmonary embolism) within 6 months prior to the first dose of study drug.

  10. Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation.

  11. Known allergies, hypersensitivity, or intolerance to IBI3003 or its excipients (refer to Investigator's Brochure).

  12. Prior toxicities that have not resolved to ≤Grade 1 prior to study treatment administration except for stable chronic toxicities (≤Grade 2) not expected to resolve (e.g., stable Grade 2 peripheral neurotoxicity)

  13. Prior antitumor therapy as follows, prior to the first dose of study drug:

    • Gene modified adoptive cell therapy (e.g., chimeric antigen receptor modified T cells, natural killer cells) within 8 weeks.
    • Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer.
    • Antibody treatment (e.g., monoclonal antibody, bispecific antibody) for multiple myeloma within 21 days.
    • Cytotoxic therapy (including antibody-drug conjugates) within 14 days.
    • Proteasome inhibitor therapy within 14 days Immunomodulatory agent therapy within 7 days.
    • Radiotherapy within 21 days. However, if the radiation field covered ≤5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy.
    • Cancer vaccine received within 3 months.
  14. Use of immunosuppressive therapy within 28 days of the start date of study treatment.

    Immunosuppressive therapy includes, but is not limited to, cyclosporine A, tacrolimus, and mycophenolate mofetil, but does not include corticosteroids given as part of an antimyeloma regimen. Participants receiving corticosteroids must be at a dose level ≤10 mg/day of prednisone equivalent for at least 7 days prior to the start of study treatment administration.

  15. Live or live attenuated vaccine administered within 4 weeks prior to start of study treatment, or anticipated need for live or live attenuated vaccine during the study.

  16. Uncontrolled diseases, including:

    • Uncontrolled infection or infection requiring systemic antibiotics, antivirals or antifungals within one week prior to first administration of the study drug;
    • Known human immunodeficiency virus (HIV) infection, or HIV positive (HIV 1/2 Ab positive);
    • For participants in mainland China, acute or chronic active hepatitis B (HBsAg positive and/or HBcAb positive with HBV DNA titer ≥104 copies/mL or ≥2000 IU/mL) or C (HCV Ab positive with HCV RNA>103 copies/mL). For participants outside of mainland China, active, latent or incompletely treated infection with HBV or HCV;
    • Failed to complete anti-tuberculosis therapy at any point prior to C1D1; active tuberculosis infection, or still on anti-tuberculosis therapy;
    • Active syphilis infection requiring treatment;
    • Symptomatic congestive heart failure Grade II-IV (New York Heart Association [NYHA]), symptomatic or uncontrolled arrhythmias, QTc interval (calculate using the Fridericia formula) >480 ms, or personal or family history of congenital long/short QT syndrome;
    • Uncontrollable hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg);
    • Active autoimmune diseases, including but not limited to inflammatory bowel disease, autoimmune hepatitis, demyelinating lesions, extensive dermatitis, immunerelated interstitial pneumonia, or Grave's disease requiring antithyroid medication control (vitiligo, or hypothyroidism requiring hormone replacement therapy, type I diabetes requiring only insulin replacement therapy and no other systemic therapy in the past 2 years are eligible); Presence of clinically uncontrolled pleural/peritoneal effusions (participants who do not require regular drainage or who do not demonstrate significant re-accumulation of effusion for at least 72 hours after the most recent drainage can enroll).
  17. Major surgery within 2 weeks prior to the first dose of study treatment, not fully recovered from any prior surgery, or has non-minor surgery anticipated during the time the participant is expected to receive study drug or within 2 weeks after the last dose of study drug administration.

  18. Participating in any other interventional clinical research except an observational (noninterventional) study or the survival follow-up phase of an interventional study.

  19. Currently pregnant or breastfeeding.

  20. Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

  21. Inability to comprehend or unwilling to sign the ICF

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:IBI3003

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Adverse events (AEs)
時間枠:Up to 30 days post last dose

Number of patients who Experienced related AEs from the first dose until 30 days after the last dose

Up to 30 days post last dose
Dose limiting toxicities (DLTs)
時間枠:Up to 28 days post first dose

To evaluate the safety and tolerability of IBI3003

Up to 28 days post first dose
ORR
時間枠:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003
時間枠:up to 24 months

To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003

up to 24 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence and characterization of anti-drug antibody (ADA).
時間枠:up to 24 months

To evaluate the immunogenicity of IBI3003

up to 24 months
Preliminary efficacy including objective response rate (ORR)
時間枠:up to 24 months

objective response rate. To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
To evaluate minimal residual disease (MRD) negativity rates. MRD negativity rate.
時間枠:up to 24 months

To evaluate minimal residual disease (MRD) negativity rates.

up to 24 months
efficacy estimates sCRR
時間枠:up to 24 months

stringent complete response rate. To evaluate other efficacy estimates of IBI3003 in the participant population.

up to 24 months
Incidence of TEAEs
時間枠:up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
half-life (T1/2)
時間枠:up to 24 months

To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
time to maximum concentration (Tmax)
時間枠:up to 24 months

time to peak concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
maximum concentration (Cmax)
時間枠:peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months

peak plasma concentration. To characterize the pharmacokinetic (PK) profile of IBI3003.
area under the curve (AUC)
時間枠:up to 24 months

area under the curve. To characterize the pharmacokinetic (PK) profile of IBI3003.

up to 24 months
complete response rate (CRR)
時間枠:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
very good partial response rate (VGPRR)
時間枠:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
duration of response (DoR)
時間枠:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
disease control rate (DCR)
時間枠:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
time to response (TTR)
時間枠:To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.
progression free survival (PFS).
時間枠:up to 24 months

To evaluate the preliminary efficacy of IBI3003 in the specified participant population.

up to 24 months
SAEs
時間枠:up to 24 months

serious adverse events (SAEs) Adverse events will be assessed by investigator(s) To evaluate the safety of IBI3003 in the participant population.

up to 24 months
changes in laboratory parameters
時間枠:up to 24 months

To evaluate the safety of IBI3003 in the participant population.

up to 24 months
physical examination findings
時間枠:up to 24 months

A complete physical examination will include: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and pharynx), lymph nodes, thyroid, musculoskeletal (including spine and extremities), genital/anal, and neurological assessments, if indicated. Clinically significant abnormal findings at screening will be recorded as medical history or AE based on the investigator's analysis and judgment.To evaluate the safety of IBI3003 in the participant population.

up to 24 months
vital signs
時間枠:up to 24 months

Collection of vital signs will include temperature in ℃, measurement tool is physiological parameter.To evaluate the safety of IBI3003 in the participant population.

up to 24 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月30日

一次修了 (推定)

2027年6月30日

研究の完了 (推定)

2028年9月30日

試験登録日

最初に提出

2026年1月8日

QC基準を満たした最初の提出物

2026年1月12日

最初の投稿 (実際)

2026年1月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CIBI3003A101EX

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。